Intrinsiqq
Metavia Inc. logo

Metavia Inc. Financials

MTVA

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 11 available years
Income Statement
DEC 2025
~2.5:1 split
DEC 2024
~1.5:1 split
DEC 2023
~15.8:1 split
DEC 2022
~3.3:1 split
DEC 2021
~1.4:1 split
Cost of Revenue–$0$0$8$0
General & Administrative$7$7$7$9$9
Research & Development$7$22$9$3$7
Total Operating Expenses$14$29$16$20$15
Operating Income-$14-$29-$16-$20-$15
Other Non-Operating Income (Expense)$1$1$3$6$0
EBT (Earnings Before Tax)-$13-$28-$12-$14-$15
Income Tax Expense$0$0$0$0$0
Net Income
Net Income-$13-$28-$12-$14-$15
EPS (Basic)-$7.35-$39.13-$27.06-$477.62-$1,743.28
EPS (Diluted)-$7.35-$39.13-$27.06-$477.62-$1,743.28
Weighted Avg Shares (Basic)1.8M7.8M5.1M2.6M23.1M
Weighted Avg Shares (Diluted)1.8M7.8M5.1M2.6M23.1M
Shares Outstanding1.8M705,193.455461,009.18229,245.7278,766.588

Metavia (MTVA) financials: revenue, profit and margins

Metavia (MTVA) generated about n/a in revenue and -$16 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Metavia profitable?+

Metavia reported about -$16 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 9 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MTVA

CompareIntrinsic value
BNTCBenitec Biopharma Inc.
$7.92-2.76%10
FBIOFortress Biotech Inc.
$1.90+7.34%59
BFRIBiofrontera Inc.
$0.53-7.02%30
ALLRAllarity Therapeutics Inc.
$0.79-8.82%0
VRCAVerrica Pharmaceuticals Inc.
$2.74-5.03%40
VYNEVyne Therapeutics Inc.
$12.90-9.35%36
TVRDCara Therapeutics Inc.
$0.99+4.55%20
AARDAardvark Therapeutics, Inc.
$0.92-7.74%10

Spot a number that looks wrong? Check it in MTVA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing MTVA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.